0001209191-23-044094.txt : 20230802
0001209191-23-044094.hdr.sgml : 20230802
20230802081736
ACCESSION NUMBER: 0001209191-23-044094
CONFORMED SUBMISSION TYPE: 3
PUBLIC DOCUMENT COUNT: 2
CONFORMED PERIOD OF REPORT: 20230801
FILED AS OF DATE: 20230802
DATE AS OF CHANGE: 20230802
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Lukowiak Andrew A
CENTRAL INDEX KEY: 0001988083
FILING VALUES:
FORM TYPE: 3
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-40047
FILM NUMBER: 231133812
MAIL ADDRESS:
STREET 1: 1639 WINDEMERE DRIVE
CITY: SAN MARCOS
STATE: CA
ZIP: 92078
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Talis Biomedical Corp
CENTRAL INDEX KEY: 0001584751
STANDARD INDUSTRIAL CLASSIFICATION: LABORATORY ANALYTICAL INSTRUMENTS [3826]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 1100 ISLAND DRIVE
STREET 2: SUITE 101
CITY: REDWOOD CITY
STATE: CA
ZIP: 94065
BUSINESS PHONE: 650-433-3000
MAIL ADDRESS:
STREET 1: 1100 ISLAND DRIVE
STREET 2: SUITE 101
CITY: REDWOOD CITY
STATE: CA
ZIP: 94065
FORMER COMPANY:
FORMER CONFORMED NAME: SlipChip Corp
DATE OF NAME CHANGE: 20130820
3
1
doc3.xml
FORM 3 SUBMISSION
X0206
3
2023-08-01
1
0001584751
Talis Biomedical Corp
TLIS
0001988083
Lukowiak Andrew A
C/O TALIS BIOMEDICAL CORP
1100 ISLAND DRIVE SUITE 101
REDWOOD CITY
CA
94065
0
1
0
1
President
Chief Scientific Officer
/s/ Rebecca Markovich, Attorney-in-fact for Andrew A. Lukowiak
2023-08-02
EX-24
2
poa.txt
POA DOCUMENT
POWER OF ATTORNEY
Know all by these presents, that the undersigned hereby constitutes and appoints
each of REBECCA L. MARKOVICH and GILLIAN GREEN, signing individually, the
undersigned's true and lawful attorneys-in-fact and agents to:
(1) prepare, execute in the undersigned's name and on the undersigned's behalf,
and submit to the United States Securities and Exchange Commission (the "SEC") a
Form ID, including amendments thereto, and any other documents necessary or
appropriate to obtain codes and passwords enabling the undersigned to make
electronic filings with the SEC of reports required by Section 16(a) of the
Securities Exchange Act of 1934, as amended (the "Exchange Act") or any rule or
regulation of the SEC;
(2) execute for and on behalf of the undersigned, in the undersigned's capacity
as an officer, director or beneficial owner of more than 10% of a registered
class of securities of TALIS BIOMEDICAL CORPORATION (the "Company"), Forms 3, 4
and 5 (including any amendments thereto) in accordance with Section 16(a) of the
Exchange Act and the rules thereunder; 2) do and perform any and all acts for
and on behalf of the undersigned that may be necessary or desirable to execute
such Forms 3, 4 or 5 or Form ID (including any amendments thereto) and timely
file such forms with the SEC and any stock exchange or similar authority; and
(3) take any other action of any nature whatsoever in connection with the
foregoing which, in the opinion of such attorney-in-fact, may be of benefit, in
the best interest of, or legally required by, the undersigned, it being
understood that the documents executed by such attorney-in-fact on behalf of the
undersigned pursuant to this Power of Attorney shall be in such form and shall
contain such terms and conditions as such attorney-in-fact may approve in such
attorney-in-fact's discretion.
The undersigned hereby grants to each such attorney-in-fact full power and
authority to do and perform any and every act and thing whatsoever requisite,
necessary or proper to be done in the exercise of any of the rights and powers
herein granted, as fully to all intents and purposes as the undersigned might or
could do if personally present, with full power of substitution or revocation,
hereby ratifying and confirming all that such attorney-in-fact, or such
attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be
done by virtue of this power of attorney and the rights and powers herein
granted. The undersigned acknowledges that the foregoing attorneys-in-fact, in
serving in such capacity at the request of the undersigned, are not assuming,
nor is the Company assuming, any of the undersigned's responsibilities to comply
with Section 16 of the Exchange Act.
This Power of Attorney shall remain in full force and effect until the earliest
to occur of (a) the undersigned is no longer required to file Forms 3, 4 and 5
with respect to the undersigned's holdings of and transactions in securities
issued by the Company, (b) revocation by the undersigned in a signed writing
delivered to the foregoing attorneys-in-fact or (c) as to any attorney-in-fact
individually, until such attorney-in-fact is no longer employed by the Company.
IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be
executed as of July 26, 2023.
/s/ Andrew A. Lukowiak